A study of neonatal hyperbilirubinemia in a tertiary care hospital.
One of the most common reasons for admission of neonates in the Neonatal intensive care unit is indirect or unconjugated hyperbilirubinemia. Jaundice may be noticed in 60% of term babies and 80% of pre-terms.  Neonatal jaundice is the occurrence of elevated bilirubin levels in the blood. It may be physiological or pathological. If the concentration of non-conjugated bilirubin in the blood is too high, it breaches the blood brain barrier and bilirubin encephalopathy occurs with serious consequences for the child.  The etiology and risk factors for indirect neonatal hyperbilirubinemia is varied and multifactorial. A study done in Australia revealed that the incidence of severe neonatal jaundice was between 7.1 and 45 per 100,000 births and of kernicterus at 0.4-2.7. The causes and risk factors associated were ABO and other blood group incompatibilities, glucose-6-phoshate-dehydrogenase deficiency, infections, prematurity, male gender, ethnicity, breastfeeding and early hospital discharge.  Knowing the risk factors and causes would help in devising strategies in managing hyperbilirubinemia and also in counselling parents. The purpose of this study is to estimate the incidence of neonatal hyperbilirubinemia in a tertiary care hospital and to determine the underlying causes and risk factors for neonatal hyperbilirubinemia.
Materials and Methods
This retrospective study was done in a tertiary care teaching hospital. All live births in the hospital in the years 2012 and 2013 were included. Data on neonates treated for unconjugated hyperbilirubinemia in the two year period was collected. The neonates were predominantly treated with phototherapy and a small minority required exchange transfusion. History including gestational age, gender, birth weight, birth order, breast feeding, formula feeding, mode of delivery and family history of jaundice were noted. The physical examination findings revealing the presence of cephalohematoma or suspicion of sepsis was noted. Results of investigations including blood group and Rh type of mother and neonate, serum bilirubin levels, direct coombs test, retic count, peripheral smear, evidence of sepsis from C Reactive Protien, TC/DC, blood culture were collated and considered to determine the etiology and risk factors.
In the present study the total number of live births in 2012 and 2013 were 5589, and 753 neonates were treated for hyperbilirubinemia. This is shown on Table 1.
The incidence of hyperbilirubinemia in our study was 13.47%. ABO incompatibility was the most common cause, in nearly one third the cause was not known, 11.6% of the treated neonates were diagnosed with sepsis. 9.4% had Rh incompatibility and cephalohematoma was present in 4.6%. This is illustrated in Figure 1.
Among the 753 treated neonates, males slightly outnumbered females, two thirds were term neonates. Low birth weight was observed in 27.7% of neonates, 263 babies were born to multiparous mothers and 490 were delivered by primi mothers. 420 babies were delivered vaginally and 333 babies by caesarean section. The factors associated with hyperbilirubinemia is shown on Table 2.
In our study 753 neonates required either phototherapy or exchange transfusion as treatment for unconjugated hyperbilirubinemia. The incidence of hyperbilirubinemia in our study was 13.47%. The most common etiology or risk factor implicated was ABO incompatibility. These observations are similar to the results of other studies. A study done in Kahramanmaraj, Turkey concluded that ABO incompatibility was the most common cause of severe neonatal hyperbilrubinemia.  An Iranian study in Fars province revealed that the most common causes of severe indirect hyperbilirubinemia were sepsis, blood group incompatibility, G6PD deficiency, and unknown. Risk factors of severe hyperbilirubinemia were Male sex, previous siblings with severe hyperbilirubinemia, male sex, normal vaginal delivery, and breast feeding.  A Croatian study showed that neonatal jaundice was associated with birth weight, maternal infections, gestational age and premature rupture of membranes.  More than one risk factor may be present in a neonate, both preterm gestation age and blood group incompatibility may co- exist and contribute in causing hyperbilirubinemia. A review article published in North America suggested that the etiology of neonatal hyperbilirubinemia is multifactorial. Late preterm gestational age, exclusive breastfeeding, glucose-6-phosphate dehydrogenase deficiency, ABO haemolytic disease, East Asian ethnicity and a history of a sibling being treated for hyperbilirubinemia were the most common risk factors associated.  The results can show inter regional variation and studies done in different parts of the world have sometimes implicated different risk factors. 18,985 New born infants born in Sarlahi district in Nepal from May 2003 to June 2006 were studied and birth weight, difficulty in feeding, gender, primiparity, oil massage, ambient air temperature, prolonged labour and ethnicity were the major risk factors.  An Iranian study investigated the causes of neonatal hyperbilirubinemia requiring blood transfusions, 118 neonates were included in the study and the researchers revealed that the most common causes were ABO incompatibility (38.1%), unknown etiology (25.4%), Rh incompatibility (16.1%), Sepsis(8.5%) and urinary tract infection (5.1%). Vaginal delivery and exclusive breast feeding and male gender were seen more among patients who required exchange transfusion.  Some studies have also indicated that neonatal hyperbilirubinemia can result in long-term sequelae. A study in the United States included 54,795 live births and 40,063 of these children were followed up until at least 7 years of age and the study demonstrated that neonatal hyperbilirubinemia was associated with increased risk of childhood asthma.  A Taiwanese study evaluated data on 11,328 children and concluded that neonatal jaundice increases the rate and complications of childhood allergic rhinitis.  This suggests that children treated for neonatal hyperbilirubinemia may require further childhood follow up. 32.9% or nearly a third of the neonates who required treatment in our study was pre-terms. The risk of hyperbilirubinemia in pre-terms is well established. Near Term infants (35-37 weeks of gestation) are 2.4 times more likely to develop significant hyperbilirubinemia than term neonates.  In the present study in 245 (32.6%) of the neonates, no etiology or risk factor could be attributed as the cause of hyperbilirubinemia. This was similar to the study done in Mashad Iran  and in that study unknown etiology accounted for 25.4% of neonatal hyperbilirubinemia cases. A Canadian study revealed that in the majority of neonatal hyperbilirubinemia cases the underlying cause was not identified.  However a study in Catania, Italy concluded that in most cases of neonatal hyperbilirubinemia, etiology can usually be well defined.  One of the probable causes responsible for hyperbilirubinemia in our study could be glucose-6phosphate dehydrogenase deficiency, but investigations to confirm this possibility were not done in our study primarily because the requisite investigations are expensive and not affordable by all. A large proportion of the 'unknown causes' in our study might be due to glucose-6-phosphate dehydrogenase deficiency. Mass newborn screening for glucose 6 phosphate dehydrogenase deficiency in Singapore since 1965 resulted in nearly 1.6 million newborns being screened and the incidence of deficiency was 1.62%. Over the last 20 years there have been no reported cases of kernicterus with G6PD deficiency.  A study in Isfahan, Iran revealed that the overall incidence of G6PD deficiency in newborns was 3.2%.  Race, Gender and ethnicity also influence the risk of neonatal hyperbilirubinemia and its etiology, a study in the U.S. revealed that Neonatal Hyperbilirubinemia and especially resulting from glucose-6-phosphate dehydrogenase deficiency is more common among African American males.  A descriptive observational study with longitudinal design done in 109 newborns at the Institute of Postgraduate Medical Education and Research, Kolkata revealed that 14.68% of the newborns were G6PD deficient and 23.8% of them developed severe neonatal hyperbilirubinemia compared to 12.5% of non G6PD deficient who developed severe neonatal hyperbilirubinemia.  These studies indicate that G6PD deficiency is one of the more common causes of neonatal hyperbilirubinemia and it is desirable that we increase the gamut of investigations while managing hyperbilirubinemia in neonates. A Turkish study concluded that reticulocyte count, the presence of a sibling with neonatal jaundice and a positive direct antiglobulin test were good predictors for the development of significant hyperbilirubinemia and a serum bilirubin levels of 4 mg/dL and 6 mg/dL at six hours of life are good predictors of severe hyperbilirubinemia.  One of the risk factors attributed in other studies was an early discharge, some studies have advocated serum bilirubin screening. A study in Pennsylvania recommended that A pre-discharge total serum bilirubin measured as a universal policy would help in targeted intervention and follow-up in a safe, cost-effective manner.  A retrospective cohort study assessed the impact of universal bilirubin screening in 358086 infants with a gestational age of 35 weeks or less and birth weight of less than 2 Kgs and concluded that universal bilirubin screening was associated with a significantly lower incidence of severe hyperbilirubinemia but also with increased phototherapy use.  Some doctors and researchers are uneasy with frequent blood sampling and instead endorse transcutaneous bilirubin assessment. A meta-analysis of 22 studies published in 2013 concluded that transcutaneous bilirubin devices are reliable in estimating bilirubin levels in preterm infants and could reduce the frequent need of blood sampling. 
The incidence of neonatal hyperbilirubinemia in our study was 13.47% and this indicates that it is a common problem encountered in our Neonatal Intensive Care Units and Hospital. The most common risk factor associated was ABO incompatibility. Nearly a third of the cases had no attributable cause or associated risk factor. Preterm gestation, primi delivery and low birth weight also showed a strong association with neonatal hyperbilirubinemia.
[1.] Brown AK, Damus K, Kim MH, King K, Harper R, Campbell D, et al. Factors relating to readmission of term and near-term neonates in the first two weeks of life. Early Discharge Survey Group of the Health Professional Advisory Board of the Greater New York Chapter of the March of Dimes. J Perinat Med 1999; 27(4):263-75.
[2.] Mesic I, Milas V, Medimurec M, Rimar Z. Unconjugated pathological jaundice in newborns. Coll Antropol 2014; 38(1):173-8.
[3.] McGillivray A, Evans N. Severe neonatal jaundice: is it a rare event in Australia? J Paediatr Child Health 2012; 48(9):801-7.
[4.] Davutoglu M, Garipardif M, Guler E, Karabiber H, Erhan D. The etiology of severe neonatal hyperbilirubinemia and complications of exchange transfusion. Turk J Pediatr 2010; 52(2):163-6.
[5.] Najib KS, Saki F, Hemmati F, Inaloo S. Incidence, risk factors and causes of severe neonatal hyperbilirubinemia in the South of Iran (Fars province). Iran Red Crescent Med J 2013; 15(3):260-3.
[6.] Watchko JF. Identification of neonates at risk for hazardous hyperbilirubinemia: emerging clinical insights. Pediatr Clin North Am 2009; 56(3):671-87.
[7.] Scrafford CG, Mullany LC, Katz J, Khatry SK, LeClerq SC, Darmstadt GL, et al. Incidence of and risk factors for neonatal jaundice among newborns in southern Nepal. Trop Med Int Health 2013; 18(11):1317-28.
[8.] Heydarian F, Majdi M. Severe neonatal hyperbilirubinemia; causes and contributing factors leading to exchange transfusion at Ghaem Hospital in Mashhad. Acta Med Iran 2010; 48(6):399-402.
[9.] Huang L, Bao Y, Xu Z, Lei X, Chen Y, Zhang Y, et al. Neonatal bilirubin levels and childhood asthma in the US Collaborative Perinatal Project, 1959-1965. Am J Epidemiol 2013; 178(12):1691-7.
[10.] Sun HL, Lue KH, Ku MS. Neonatal jaundice is a risk factor for childhood allergic rhinitis: a retrospective cohort study. Am J Rhinol Allergy 2013; 27(3):192-6.
[11.] Sarici SU, Serdar MA, Korkmaz A, Erdem G, Oran O, Tekinalp G, et al. Incidence, course, and prediction of hyperbilirubinemia in near-term and term newborns. Pediatrics 2004; 113(4):775-80.
[12.] Sgro M, Campbell D, Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ 2006; 175(6):587-90.
[13.] Sciuto M, Bertino G, Zocco M, Vecchio I, Raffaele R, Trifiletti RR, et al. Incidence and causes of neonatal hyperbilirubinemia in a center of Catania. Ther Clin Risk Manag 2009; 5(1):247-50.
[14.] Joseph R, Ho LY, Gomez JM, Rajdurai VS, Sivasankaran S, Yip YY. Mass newborn screening for glucose-6-phosphate dehydrogenase deficiency in Singapore. Southeast Asian J Trop Med Public Health 1999; 30 (Suppl 2):70-1.
[15.] Iranpour R, Hashemipour M, Talaei SM, Soroshnia M, Amini A. Newborn screening for glucose-6-phosphate dehydrogenase
deficiency in Isfahan, Iran: a quantitative assay. J Med Screen 2008; 15(2):62-4.
[16.] Kaplan M, Herschel M, Hammerman C, Hoyer JD, Heller GZ, Stevenson DK. Neonatal hyperbilirubinemia in African American males: the importance of glucose-6-phosphate dehydrogenase deficiency. J Pediatr 2006; 149(1):83-8.
[17.] Bisoi S, Chakraborty S, Chattopadhyay D, Biswas B, Ray S. Glucose-6-phosphate dehydrogenase screening of babies born in a tertiary care hospital in West Bengal. Indian J Public Health 2012; 56(2):146-8.
[18.] Sarici SU, Yurdakok M, Serdar MA, Oran O, Erdem G, Tekinalp G, et al. An early (sixth-hour) serum bilirubin measurement is useful in predicting the development of significant hyperbilirubinemia and severe ABO hemolytic disease in a selective high-risk population of newborns with ABO incompatibility. Pediatrics 2002; 109(4).
[19.] Bhutani VK, Johnson L, Sivieri EM. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics 1999; 103(1):6-14.
[20.] Kuzniewicz MW, Escobar GJ, Newman TB. Impact of universal bilirubin screening on severe hyperbilirubinemia and phototherapy use. Pediatrics 2009; 124(4):1031-9.
[21.] Nagar G, Vandermeer B, Campbell S, Kumar M. Reliability of transcutaneous bilirubin devices in preterm infants: a systematic review. Pediatrics 2013; 132(5):871-81.
Source of Support: Nil
Conflict of interest: None declared
Anil Shetty, Binoop S Kumar
Department of Paediatrics, Father Muller Medical College, Mangalore, Karnataka, India
Correspondence to: Anil Shetty (email@example.com)
Received Date: 18.07.2014
Accepted Date: 01.08.2014
Table-1: Total Live births and neonates treated for Year Live Births Neonatal Hyperbilirubinemia 2012 2611 364 2013 2978 389 Total 5589 753 Table-2: Factors associated with unconjugated neonatal hyperbilirubinemia Factors Associated Number Percentage Gender Male 403 53.5 Female 350 46.5 Gestational Age Term 506 67.1 Preterm 247 32.9 Birth Weight Low Birth Weight 105 13.9 Very Low Birth Weight 70 9.3 Extremely Low 35 4.6 Birth Weight Parity Primi 490 65.1 Multi 263 34.9 Mode of Caesarean Section 333 44.2% Delivery Normal Vaginal Delivery 420 55.8% Figure-1: Causes of neonatal hyperbilirubinemia Sepsis 87 Cephalohematoma 35 ABO incompatibility 318 Rh Incompatibility 71 Unknown 245 Note: Table made from pie chart.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RESEARCH ARTICLE|
|Author:||Shetty, Anil; Kumar, Binoop S.|
|Publication:||International Journal of Medical Science and Public Health|
|Date:||Oct 1, 2014|
|Previous Article:||Gestational diabetes: perinatal and maternal complication in 24-28 weeks.|
|Next Article:||Effects of lifestyle habits on the prevalence of obesity among school going adolescents residing in urban Lucknow.|